These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 25806823)
1. Correction: Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLOS ONE Staff PLoS One; 2015; 10(3):e0121882. PubMed ID: 25806823 [No Abstract] [Full Text] [Related]
2. Correction: Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes. Pane M; Mazzone ES; Sivo S; Sormani MP; Messina S; D'Amico A; Carlesi A; Vita G; Fanelli L; Berardinelli A; Torrente Y; Lanzillotta V; Viggiano E; D'Ambrosio P; Cavallaro F; Frosini S; Barp A; Bonfiglio S; Scalise R; De Sanctis R; Rolle E; Graziano A; Magri F; Palermo C; Rossi F; Donati MA; Sacchini M; Arnoldi MT; Baranello G; Mongini T; Pini A; Battini R; Pegoraro E; Previtali S; Bruno C; Politano L; Comi GP; Bertini E; Mercuri E PLoS One; 2015; 10(12):e0144079. PubMed ID: 26636671 [No Abstract] [Full Text] [Related]
3. Correction: Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. Brogna C; Coratt G; Pane M; Ricotti V; Messina S; D'Amico A; Bruno C; Vita G; Berardinelli A; Mazzone E; Magri F; Ricci F; Mongini T; Battini R; Bello L; Pegoraro E; Baranello G; Previtali SC; Politano L; Comi GP; Sansone VA; Donati A; Bertini E; Muntoni F; Goemans N; Mercuri E; PLoS One; 2019; 14(7):e0220714. PubMed ID: 31365579 [TBL] [Abstract][Full Text] [Related]
4. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Biggar WD; Politano L; Harris VA; Passamano L; Vajsar J; Alman B; Palladino A; Comi LI; Nigro G Neuromuscul Disord; 2004 Sep; 14(8-9):476-82. PubMed ID: 15336688 [TBL] [Abstract][Full Text] [Related]
6. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. King WM; Ruttencutter R; Nagaraja HN; Matkovic V; Landoll J; Hoyle C; Mendell JR; Kissel JT Neurology; 2007 May; 68(19):1607-13. PubMed ID: 17485648 [TBL] [Abstract][Full Text] [Related]
7. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids. Goemans N; van den Hauwe M; Wilson R; van Impe A; Klingels K; Buyse G Neuromuscul Disord; 2013 Aug; 23(8):618-23. PubMed ID: 23770101 [TBL] [Abstract][Full Text] [Related]
8. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial. Kirschner J; Schessl J; Schara U; Reitter B; Stettner GM; Hobbiebrunken E; Wilichowski E; Bernert G; Weiss S; Stehling F; Wiegand G; Müller-Felber W; Thiele S; Grieben U; von der Hagen M; Lütschg J; Schmoor C; Ihorst G; Korinthenberg R Lancet Neurol; 2010 Nov; 9(11):1053-9. PubMed ID: 20801085 [TBL] [Abstract][Full Text] [Related]
9. Assisted bicycle training delays functional deterioration in boys with Duchenne muscular dystrophy: the randomized controlled trial "no use is disuse". Jansen M; van Alfen N; Geurts AC; de Groot IJ Neurorehabil Neural Repair; 2013; 27(9):816-27. PubMed ID: 23884013 [TBL] [Abstract][Full Text] [Related]
11. A 19-year-old ambulant Duchenne patient with stunted growth on long-term corticosteroids. Merlini L Neuromuscul Disord; 2014 May; 24(5):417-8. PubMed ID: 24631208 [No Abstract] [Full Text] [Related]
12. Intellectual and behavioral functioning in a South african cohort of boys with duchenne muscular dystrophy. Donald KA; Mathema H; Thomas KG; Wilmshurst JM J Child Neurol; 2011 Aug; 26(8):963-9. PubMed ID: 21527393 [TBL] [Abstract][Full Text] [Related]
13. The impact of deflazacort on puberty in Duchenne muscular dystrophy. Dooley JM; Bobbitt SA; Cummings EA Pediatr Neurol; 2013 Oct; 49(4):292-3. PubMed ID: 23921283 [TBL] [Abstract][Full Text] [Related]
14. Changes in center of gravity in boys with Duchenne muscular dystrophy. Barrett R; Hyde SA; Scott OM; Dubowitz V Muscle Nerve; 1988 Nov; 11(11):1157-63. PubMed ID: 3226433 [TBL] [Abstract][Full Text] [Related]
15. Electromyographic pattern in Duchenne and Becker muscular dystrophy. Part II. Electromyographic pattern in Becker muscular dystrophy in comparison with Duchenne muscular dystrophy. Emeryk-Szajewska B; Kopeć J Electromyogr Clin Neurophysiol; 2008; 48(6-7):279-84. PubMed ID: 18837193 [TBL] [Abstract][Full Text] [Related]
16. Progression of equinus deformity in Duchenne muscular dystrophy. Seeger BR; Caudrey DJ; Little JD Arch Phys Med Rehabil; 1985 May; 66(5):286-8. PubMed ID: 4004517 [TBL] [Abstract][Full Text] [Related]
17. [Pain, osteopenia and body composition of 22 patients with Duchenne muscular dystrophy: a descriptive study]. Douvillez B; Braillon P; Hodgkinson I; Berard C Ann Readapt Med Phys; 2005 Nov; 48(8):616-22. PubMed ID: 16023755 [TBL] [Abstract][Full Text] [Related]
18. An examination of some factors influencing creatine kinase in the blood of patients with muscular dystrophy. Jackson MJ; Round JM; Newham DJ; Edwards RH Muscle Nerve; 1987 Jan; 10(1):15-21. PubMed ID: 3561434 [TBL] [Abstract][Full Text] [Related]
19. Duchenne muscular dystrophy: issues in expanding newborn screening. Kemper AR; Wake MA Curr Opin Pediatr; 2007 Dec; 19(6):700-4. PubMed ID: 18025940 [TBL] [Abstract][Full Text] [Related]
20. Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. Beenakker EA; Maurits NM; Fock JM; Brouwer OF; van der Hoeven JH Eur J Paediatr Neurol; 2005; 9(6):387-93. PubMed ID: 16102988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]